In last trading session, Century Therapeutics Inc (NASDAQ:IPSC) saw 1.23 million shares changing hands with its beta currently measuring 1.50. Company’s recent per share price level of $1.63 trading at $0.28 or 20.74% at ring of the bell on the day assigns it a market valuation of $167.35M. That closing price of IPSC’s stock is at a discount of -238.04% from its 52-week high price of $5.51 and is indicating a premium of 30.06% from its 52-week low price of $1.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.67 million shares which gives us an average trading volume of 408.34K if we extend that period to 3-months.
For Century Therapeutics Inc (IPSC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.44 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Century Therapeutics Inc (NASDAQ:IPSC) trade information
Century Therapeutics Inc’s shares saw a change of -50.90% in year-to-date performance and have moved 29.37% in past 5-day. Century Therapeutics Inc (NASDAQ:IPSC) showed a performance of 19.85% in past 30-days. Number of shares sold short was 2.26 million shares which calculate 5.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 88.36% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 27. It follows that stock’s current price would drop -206.75% in reaching the projected high whereas dropping to the targeted low would mean a loss of -206.75% for stock’s current value.
Century Therapeutics Inc (IPSC) estimates and forecasts
Statistics highlight that Century Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -47.08% of value to its shares in past 6 months, showing an annual growth rate of 21.63% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 47.16% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 975k for the same. And 3 analysts are in estimates of company making revenue of 633.33k in the next quarter. Company posted 268k and 855k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.24% during past 5 years.
Century Therapeutics Inc (NASDAQ:IPSC)’s Major holders
Insiders are in possession of 28.36% of company’s total shares while institution are holding 59.50 percent of that, with stock having share float percentage of 83.05%. Investors also watch the number of corporate investors in a company very closely, which is 59.50% institutions for Century Therapeutics Inc that are currently holding shares of the company. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the top institutional holder at IPSC for having 5.41 million shares of worth $13.8 million. And as of 2024-06-30, it was holding 8.6848 of the company’s outstanding shares.
The second largest institutional holder is VR ADVISER, LLC, which was holding about 5.39 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.651 of outstanding shares, having a total worth of $13.74 million.
On the other hand, iShares Russell 2000 ETF and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 31, 2024 , the former fund manager was holding 1.07 shares of worth $1.74 million or 1.26% of the total outstanding shares. The later fund manager was in possession of 785.57 shares on Jun 30, 2024 , making its stake of worth around $1.28 million in the company or a holder of 0.92% of company’s stock.
